Sign In
Buy DYAI
$1.06
-0.0100 (-0.93%)
At Close: Jul 10, 2026
Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential
07:25am, Tuesday, 07'th Jul 2026
Global Collaborations Continue to Validate Dyadic's C1 Platform and Expand Commercial Opportunity Dyadic's Ebola preparedness work highlights C1's potentia
Dyadic Expands IP Protection and Business Development Activities in Japan
07:25am, Monday, 29'th Jun 2026
JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on th
An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets
08:46am, Monday, 22'nd Jun 2026
SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partnerships, and Long-Term Growth Vision New York, New York--(Newsfile Corp. - June 22, 2026) - Dyadic Appl
JUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions (“Dyadic” or the “Company”), a biotechnology company focused on th
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
07:25am, Thursday, 28'th May 2026
JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a biot
Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
04:05pm, Thursday, 21'st May 2026
JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a glob
Company invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™ Company invites individu
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
09:35am, Tuesday, 19'th May 2026
JUPITER, Fla. , May 19, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic," "we," "us," "our," or the "Company") (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology co
Dyadic International, Inc. (DYAI) Q1 2026 Earnings Call Transcript
04:40am, Thursday, 14'th May 2026
Dyadic International, Inc. (DYAI) Q1 2026 Earnings Call Transcript
Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
04:05pm, Wednesday, 13'th May 2026
Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industry Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Bi
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
04:05pm, Wednesday, 29'th Apr 2026
JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology co
Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript
03:25am, Thursday, 26'th Mar 2026
Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
04:51pm, Wednesday, 25'th Mar 2026
Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product sales
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
07:20am, Monday, 16'th Mar 2026
JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company produci
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
04:10pm, Wednesday, 11'th Mar 2026
JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology co
